Melanoma, the First mRNA Therapeutic Vaccine in History Works: Built (in 6 Weeks) Starting From the Cancer Removed From Each Patient
6 Articles
6 Articles
The mRNA personalized therapeutic vaccine has passed the test of a large phase 3 study. The results presented at the Emo Congress in Madrid open a new frontier in the fight against cancer and Italy is protagonist.
The risk of relapse and remote metastasis is reduced in people who are radically operated on cancer. The INT in Milan is the Centre that has involved the largest number of patients in the world in the study.
The addition of a custom mRNA vaccine to standard immunotherapy reduces the risk of relapse by 42% and by 38% that of developing remote metastases in patients operated for high-risk melanoma, according to the 24-month data of an international phase 3 study presented at Esmo 2026. To explain it is Michele Del... Read more L'articolo Melanoma, Del Vecchio (Int), with customized vaccine -42% the risk of relapse is from Five Columns Magazine.
Rec News | Lontani dal mainstream
notizie.itThe addition of a custom mRNA vaccine to standard immunotherapy reduces the risk of relapse by 42% and by 38% that of developing remote metastases in patients operated for high-risk melanoma, according to the 24-month data of an international phase 3 study presented to Esmo 2026. To explain it is Michele Del [...] The article Melanoma, Del Vecchio (Int), with customized vaccine -42% the risk of relapse is from Rec News.
In Esmo 2026 the results of an international phase 3 study: benefits from the addition of the personalized vaccine to immunotherapy. The National Cancer Institute of Milan is the center with several patients enrolled in the world. 'The addition of a personalized vaccine to mRNA all'immunotherapy with pembrolizumab improves the results in patients operated for high-risk melanoma'. It explains this to the Adnkron9s Salute Michele Del Vecchio, resp…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
